-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This report will review the current domestic ADC development from the perspectives of development companies, investment and financing, and authorized introduction
Classified by development company, local companies come from behind
According to the statistics of R&D customers, according to the classification of development companies, there are 25 domestic domestic companies that have deployed ADC pipelines, and 77 products have been developed, accounting for 89% of the total products
Meyac Bio has four ADCs including MRG001, MRG002, MRG003, and MRG004A that have entered the late stage of IND.
Domestic local companies are actively deploying ADC pipelines, including companies such as Kelun Pharmaceutical, CSPC, Duoxi Biological, Fudan Zhangjiang, Qilu Pharmaceutical, etc.
The ADC R&D boom has also attracted many cutting-edge companies to devote themselves to R&D
Independent research and development or license introduction
As of July 19, 2021, domestic local companies have counted 77 ADC products (not including published patents)
Among the licensed products, Genting Xinyao’s Gosartuzumab has submitted a marketing application, and the remaining three products in phase III clinical phases are Huadong Medicine’s IMGN853, Qilu Pharmaceutical’s VB4-845 and Xinma Bio’s ARX788
In addition, on June 29, Innovent and ADC technology platform company Synaffix reached a cooperation, introduced GlycoConnect™, HydraSpace™ and a certain connector-toxin under the toxSYN™ platform, and officially entered the ADC field
ADC financing market is hot
The ADC R&D boom has also attracted the attention of the capital market.
As of now, there have been 10 ADC drug investment and financing events in 2021
.
Among them, Duoxi Bio's Series C financing of 1 billion yuan is the largest financing by transaction volume, which is jointly led by Hillhouse Ventures, Chenling Capital and CPE
.
Duoxi Biologics has 3 ADC drugs that have entered clinical trials.
Trop2 monoclonal antibody-Tub196 coupling agent (DAC-002) and HER2 monoclonal antibody-Tub114 coupling agent (DAC-001) are in clinical phase I, targeting MUC1's ADC has recently been approved for clinical use in advanced solid tumors, which is the first in China
.
Qilu Pharmaceutical's MUC1 targeting drug PAb001-ADC imported from Peptron has not yet been applied for clinical application
.
Since its establishment in 2012, Duoxi Bio has been committed to the development of ADC innovative drugs, and its not to be underestimated R&D strength has also attracted Junshi Bio to jointly develop DAC-002
.
Kai Tak Pharmaceuticals also completed the C round of financing.
The first ADC product to be declared for clinical use is GQ1001, which targets HER2
.
Domestic HER2 conjugated drugs have shown a homogenization trend.
GQ1001 uses transpeptidase-specific coupling technology.
The preferred indication is triple-negative breast cancer.
It is expected that it will contribute different data in the ADC market
.
This year’s ADC capital market has also ushered in a harvest period.
Connoa Bio has officially listed on the Hong Kong Stock Exchange on July 8.
CMG901 in the product pipeline is the first Claudin 18.
2 targeted ADC product in China to declare clinical trials.
Arco Bio is cooperating in research and development, and is currently carrying out a phase I clinical trial for the treatment of advanced solid tumors
.
On the other hand, Lepu Biotech announced the completion of Series C financing on April 20, and its holding subsidiary Meyac Biotech owns 6 ADC products
.
Not long after the C round of financing, Lepu Bio submitted an IPO application to the Hong Kong Stock Exchange
.
Rongchang Bio also submitted its IPO on the Science and Technology Innovation Board in June and was accepted.
Since its listing on the Hong Kong Stock Exchange in November 2020, Rongchang Bio has two innovative drugs approved for listing, especially the first domestic ADC approved recently.
Vedicitumumab
.
In addition, the cutting-edge ADC companies that completed the A and B rounds of financing in the first half of this year include Pufang Bio, Yilian Bio, Blixco and Yingen Bio.
In addition to Blixco's BB-1701, it is currently undergoing phase I clinical trials.
, The product pipelines of other companies are still in pre-clinical
.
annex: